Is this used for endometrial cancer?
Key Points
Lenvatinib is considered a targeted drug therapy and pembrolizumab is an immunotherapy agent. These drugs can work together in different ways to help treat advanced endometrial cancer.
How do I know if I have a MSI-H/dMMR cancer?
In the body, the DNA mismatch repair (MMR) system helps to correct errors that may occur during DNA replication. Problems with the MMR system can lead to microsatellite instability-high (MSI-H). These types of cancers have errors in their generic sequences that may be repeated (called microsatellites). MSI-H/dMMR may occur when a cell is unable to repair these errors made during division.
To find out if you have cancer that contains a biomarker for MSI-H/dMMR, a sample of tissue is taken and a test is ordered that will examine your tissue. Many types of cancer are examined for MSI-H/dMMR biomarkers. Roughly 75% of endometrial cancer cases are not microsatellite instability-high or mismatch repair deficient.
Women with endometrial cancer are eligible for lenvatinib plus pembrolizumab if:
Studies are ongoing to determine the effectiveness of lenvatinib plus pembrolizumab regardless of tumor MSI status.
In March 2022, pembrolizumab (Keytruda) as a single agent (called monotherapy) was approved for treatment of patients with advanced endometrial carcinoma that IS microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-approved test. In addition, these patients have had disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
What are the study results for lenvatinib / pembrolizumab?
Lenvatinib plus pembrolizumab was evaluated in a study (KEYNOTE-146) with 94 patients with metastatic endometrial cancer that had continued to worsen after at least one prior systemic therapy.
Lenvatinib and pembrolizumab combination treatment showed an overall response rate (ORR) of 38.3%, with a partial response rate of 27.7% and a complete response rate of 10.6%. Patients were followed up for a median of 18.7 months. ORR is the percent of patients whose tumor is destroyed (complete) or reduced in size (partial) by a drug.
At data cut-off, the median duration of response was not reached, but had a range of 1.2 to 33.1 months, or longer. Sixty-nine percent of patients had a response lasting 6 months or longer.
Serious and possibly fatal side effects can occur with the use of lenvatinib and pembrolizumab for endometrial cancer. Immune-mediated reactions, infusion reactions, and other serious side effects can occur. Serious side effects occurred in over 50% of patients in studies, and 3% were fatal. There are also many common, but less serious side effects with this drug combination.
Speak with your doctor to understand the risk for side effects before treatment.
Bottom Line
This is not all the information you need to know about lenvatinib and pembrolizumab for safe and effective use. Review the full drug product information at the above links and discuss this information, and any questions you have, with your doctor or other health care provider.
Related medical questions
- How long do you take Lenvima?
- How effective is Lenvima?
- How long does it take for Lenvima to work?
- What type of drug is Lenvima? Is it a chemo drug?
- Is this an immunotherapy or chemotherapy drug?
- How long does it take to work?
- Lenvatinib vs sorafenib: for first line treatment in HCC?
- Is this used for endometrial cancer?
- How does it work?
- How long do you take Lenvima?
- How effective is Lenvima?
- How long does it take for Lenvima to work?
- Is this an immunotherapy or chemotherapy drug?
- How long does it take to work?
- What type of drug is Lenvima? Is it a chemo drug?
- Lenvatinib vs sorafenib: for first line treatment in HCC?
- Is this used for endometrial cancer?
- How does it work?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions